Changchuan Jiang

Nov 7, 2024 | jamanetwork.com | Changchuan Jiang |K. Robin Yabroff |Ryan D. Nipp |Xuesong Han

Introduction Ondansetron, the most commonly recommended antinausea drug for patients with cancer, initially faced high list prices, prompting scrutiny and national campaigns supported by the American Society of Clinical Oncology to reduce use.1,2 However, the introduction of generic ondansetron in 2006 dramatically lowered costs and increased its value, leading to its inclusion on the World Health Organization’s essential medication list for all health systems globally.3 In the US,...